pelabresib
MorphoSys shares phase 3 trial results for pelabresib in myelofibrosis treatment
November 23, 2023Research and Development Haematology, clinical trial, morphosys, myelofibrosis, pelabresib
MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination …
